TP53

Chr 17ADSomatic

tumor protein p53

Also known as: BCC7, BMFS5, LFS1, P53, TRP53

The protein is a tumor suppressor that regulates gene expression in response to cellular stress, inducing cell cycle arrest, apoptosis, DNA repair, or metabolic changes. Mutations cause Li-Fraumeni syndrome and predispose to multiple pediatric cancers including adrenocortical carcinoma, osteosarcoma, and choroid plexus papilloma through autosomal dominant inheritance. The pathogenic mechanism involves loss of function of this critical tumor suppressor.

OMIMResearchSummary from RefSeq, OMIM, UniProt, Mechanism
LOFmechanismAD/SomaticLOEUF 0.4712 OMIM phenotypes
Clinical SummaryTP53
🧬
Gene-Disease Validity (ClinGen)
Li-Fraumeni syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.53) — some intolerance to loss-of-function variants.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.47LOEUF
pLI 0.532
Z-score 3.26
OE 0.20 (0.100.47)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
0.98Z-score
OE missense 0.82 (0.730.92)
192 obs / 234.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.20 (0.100.47)
00.351.4
Missense OE0.82 (0.730.92)
00.61.4
Synonymous OE1.07
01.21.6
LoF obs/exp: 4 / 19.5Missense obs/exp: 192 / 234.3Syn Z: -0.54
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveTP53-related Li-Fraumeni syndromeLOFAD
DN
0.77top 25%
GOF
0.82top 10%
LOF
0.75top 10%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function, gain-of-function and dominant-negative). The Badonyi & Marsh model scores gain-of-function highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports loss-of-function (haploinsufficiency). Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · 1 literature citation · LOEUF 0.47
GOFprediction above median · 1 literature citation
DNprediction above median · 1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNTogether, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.PMID:14743206
GOFZhu et al. (2015) demonstrated that p53 gain-of-function mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (KMT2A; 159555), MLL2 (KMT2D; 602113), and acetyltransferase MOZ (KAT6A; 601408), resulting in genomewide increases of histone methylation and acePMID:26331536
LOFRevisiting Li-Fraumeni Syndrome From TP53 Mutation CarriersPMID:26014290

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

TP53 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Head and Neck Carcinoma of Unknown PrimaryHead and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

ACTIVE NOT RECRUITING
NCT02567422Phase PHASE1National Cancer Institute (NCI)Started 2017-04-17
BerzosertibCisplatinComputed Tomography
Li-Fraumeni SyndromeLi-Fraumeni-Like Syndrome

Li-Fraumeni Syndrome/TP53 Biobank

RECRUITING
NCT04367246Abramson Cancer Center at Penn MedicineStarted 2019-09-24
No Intervention
Li-Fraumeni SyndromeNeoplasmsTp53 Mutations

Clinical and Genetic Studies of Li-Fraumeni Syndrome

RECRUITING
NCT01443468National Cancer Institute (NCI)Started 2012-01-17
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

ACTIVE NOT RECRUITING
NCT05396859Phase PHASE1OHSU Knight Cancer InstituteStarted 2022-10-28
Decitabine and CedazuridineEntrectinibLaboratory Biomarker Analysis
Endometrial Neoplasms

MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer

NOT YET RECRUITING
NCT06126393Fujian Cancer HospitalStarted 2024-01-01
next generation sequencing AND Immunohistochemical examination
Polycythemia VeraEssential ThrombocythaemiaMyelofibrosis

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NOT YET RECRUITING
NCT06923670Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-05-21
NGS testingNGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
AMLMDS

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

RECRUITING
NCT06972641Phase PHASE2, PHASE3Ruijin HospitalStarted 2025-06-10
DecitabineSorafenib (BAY-43-9006),giritinibAvastinib
Pancreas Cancer

ctDNA Assay in Patients With Resectable Pancreatic Cancer

RECRUITING
NCT05052671University of OklahomaStarted 2022-05-25
Non-small Cell CarcinomaEGFR Gene Mutation

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

ACTIVE NOT RECRUITING
NCT04695925Phase PHASE3Li Zhang, MDStarted 2021-03-29
OsimertinibPemetrexedCarboplatin
ALL, AdultAML, AdultAcute Leukaemia

A Study of BN104 in the Treatment of Acute Leukemia

ACTIVE NOT RECRUITING
NCT06052813Phase PHASE1, PHASE2Institut de Recherches Internationales Servier (I.R.I.S.)Started 2023-10-19
BN104 monotherapyBN104 monotherapyBN104 monotherapy - rp2d
Lung Cancer

Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer

ACTIVE NOT RECRUITING
NCT06301295Phase NAPusan National University HospitalStarted 2024-05-29
Ultarthin bronchoscopy with intratumoral washing
Prostate Cancer

Detection of Minimal Residual Disease Post-prostatectomy

RECRUITING
NCT07334275Radboud University Medical CenterStarted 2025-09-16
Clinical Literature
Open Research Assistant →
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
PubTator3
TP53 or Not TP53: That Is the Question.
Green SD et al.·Clin Cancer Res
2022
TP53
Yan X et al.·Zhonghua Xue Ye Xue Za Zhi
2025
TP53 B
Du YY et al.·Zhonghua Xue Ye Xue Za Zhi
2021
TP53 / 42
Feng D et al.·Zhonghua Xue Ye Xue Za Zhi
2023
Top 5 full-text resultsSearch PubTator3 ↗